Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells.

Published on Mar 23, 2020in Cancer immunology research8.728
· DOI :10.1158/2326-6066.CIR-19-0467
Gennaro Prota4
Estimated H-index: 4
(University of Oxford),
Uzi Gileadi28
Estimated H-index: 28
(University of Oxford)
+ 14 AuthorsVincenzo Cerundolo108
Estimated H-index: 108
(University of Oxford)
Sources
Abstract
Epitopes derived from mutated cancer proteins elicit strong antitumor T-cell responses that correlate with clinical efficacy in a proportion of patients. However, it remains unclear whether the subcellular localization of mutated proteins influences the efficiency of T-cell priming. To address this question we compared the immunogenicity of NY-ESO-1 and OVA localized either in the cytosol or in mitochondria. We showed that tumors expressing mitochondrial-localized NY-ESO-1 and OVA proteins elicit significantly higher frequencies of antigen-specific CD8+ T cells in vivo. We also demonstrated that this stronger immune response is dependent on the mitochondrial location of the antigenic proteins, which contributes to their higher steady state amount, compared with cytosolic-localized proteins. Consistent with these findings, we showed that injection of mitochondria purified from B16 melanoma cells can protect mice from a challenge with B16 cells, but not with irrelevant tumors. Finally, we extended these findings to cancer patients by demonstrating the presence of T-cell responses specific for mutated mitochondrial-localized proteins. These findings highlight the utility of prioritizing epitopes derived from mitochondrial-localized mutated proteins as targets for cancer vaccination strategies.
📖 Papers frequently viewed together
20132.74PLOS ONE
4 Citations
44 Citations
2014
1 Author (Luke Williams)
References47
Newest
#1Marine Gros (Curie Institute)H-Index: 1
#2Sebastian Amigorena (Curie Institute)H-Index: 94
Cross-priming refers to the induction of primary cytotoxic CD8+ T cell responses to antigens that are not expressed in the antigen presenting cells (APCs) that induce the priming (i.e responses to tumor antigens or to antigens from viruses that do no infect APCs). Cross-presentation names the process allowing uptake of antigens, their processing into peptides, and the subsequent loading and presentation of these peptides by Major Histocompatibility Complex (MHC) class I molecules. Despite extens...
32 CitationsSource
#1Chung-Han Lee (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 16
#2Roman YelenskyH-Index: 61
Last. Timothy A. Chan (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 92
view all 4 authors...
Antitumor rejection by the immune system is a complex process that is regulated by several factors. Among these factors are the quality and quantity of mutational events that occur in cancer cells. Perhaps one of the most important types of mutations that influence antitumor immunity is the neoantigen, that is, a non-self-antigen that arises as a result of somatic mutation. Recent work has demonstrated that neoantigens hold significant promise for developing new diagnostic and therapeutic modali...
83 CitationsSource
#1Daniel Temko (UCL: University College London)H-Index: 5
#2Inge C. van Gool (LEI: Leiden University)H-Index: 3
Last. Ian Tomlinson (University of Birmingham)H-Index: 128
view all 26 authors...
Genomic instability, which is a hallmark of cancer, is generally thought to occur in the middle to late stages of tumourigenesis, following the acquisition of permissive molecular aberrations such as TP53 mutation or whole genome doubling. Tumours with somatic POLE exonuclease domain mutations are notable for their extreme genomic instability (their mutation burden is among the highest in human cancer), distinct mutational signature, lymphocytic infiltrate, and excellent prognosis. To what exten...
32 CitationsSource
#1Sangwoo KimH-Index: 20
#2Han Sang Kim (Yonsei University)H-Index: 16
Last. Soonmyung Paik (Yonsei University)H-Index: 70
view all 6 authors...
Tumor-specific mutations form novel immunogenic peptides called neoantigens. Neoantigens can be used as a biomarker predicting patient response to cancer immunotherapy. Although a predicted binding affinity (IC50) between peptide and major histocompatibility complex class I is currently used for neoantigen prediction, large number of false-positives exist.We developed Neopepsee, a machine-learning-based neoantigen prediction program for next-generation sequencing data. With raw RNA-seq data and ...
58 CitationsSource
#1Mark Yarchoan (Johns Hopkins University)H-Index: 27
#2Alexander Hopkins (Johns Hopkins University)H-Index: 6
Last. Elizabeth M. Jaffee (Johns Hopkins University)H-Index: 90
view all 3 authors...
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
1,050 CitationsSource
#1Vinod P. Balachandran (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 28
#2Marta Łuksza (IAS: Institute for Advanced Study)H-Index: 9
Last. Cindy ForestH-Index: 1
view all 144 authors...
The analysis of T-cell antigens in long-term survivors of pancreatic ductal adenocarcinoma suggests that neoantigen immunogenicity and quality, not purely quantity, correlate with survival.
440 CitationsSource
#1Marta Łuksza (IAS: Institute for Advanced Study)H-Index: 9
#2Nadeem Riaz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 48
Last. Benjamin D. GreenbaumH-Index: 27
view all 12 authors...
An immune fitness model for tumours under checkpoint blockade immunotherapy is proposed, through which the authors show that the presentation and recognition properties of dominant neoantigens distributed over tumour subclones are predictive of response in melanoma and lung cancer cohorts.
309 CitationsSource
#1Antonella VitielloH-Index: 19
#2Maurizio Zanetti (UCSD: University of California, San Diego)H-Index: 36
48 CitationsSource
#1Freidrich M. CruzH-Index: 4
#2Jeff D. ColbertH-Index: 15
Last. Kenneth L. RockH-Index: 98
view all 5 authors...
To monitor the health of cells, the immune system tasks antigen-presenting cells with gathering antigens from other cells and bringing them to CD8 T cells in the form of peptides bound to MHC-I molecules. Most cells would be unable to perform this function because they use their MHC-I molecules to exclusively present peptides derived from the cell's own proteins. However, the immune system evolved mechanisms for dendritic cells and some other phagocytes to sample and present antigens from the ex...
114 CitationsSource
#1Anne-Mette Bjerregaard (DTU: Technical University of Denmark)H-Index: 5
#2Morten Nielsen (DTU: Technical University of Denmark)H-Index: 85
Last. Aron Charles Eklund (DTU: Technical University of Denmark)H-Index: 32
view all 5 authors...
Personalization of immunotherapies such as cancer vaccines and adoptive T cell therapy depends on identification of patient-specific neo-epitopes that can be specifically targeted. MuPeXI, the mutant peptide extractor and informer, is a program to identify tumor-specific peptides and assess their potential to be neo-epitopes. The program input is a file with somatic mutation calls, a list of HLA types, and optionally a gene expression profile. The output is a table with all tumor-specific peptid...
91 CitationsSource
Cited By2
Newest
#1Matteo Morotti (University of Oxford)H-Index: 19
#1Ahmed Ashour AhmedH-Index: 28
Last. David C. Wedge (University of Manchester)H-Index: 59
view all 21 authors...
Cancer is a leading cause of death worldwide and, despite new targeted therapies and immunotherapies, many patients with advanced-stage- or high-risk cancers still die, owing to metastatic disease. Adoptive T-cell therapy, involving the autologous or allogeneic transplant of tumour-infiltrating lymphocytes or genetically modified T cells expressing novel T-cell receptors or chimeric antigen receptors, has shown promise in the treatment of cancer patients, leading to durable responses and, in som...
4 CitationsSource
#2Wayne PaesH-Index: 6
Last. Mikhail ShugayH-Index: 27
view all 13 authors...
Human leukocyte antigen (HLA) is highly polymorphic and plays a key role in guiding adaptive immune responses by presenting foreign and self peptides to T cells. Each HLA variant selects a minor fraction of peptides that match a certain motif required for optimal interaction with the peptide-binding groove. These restriction rules define the landscape of peptides presented to T cells. Given these limitations, one might suggest that the choice of peptides presented by HLA is non-random and there ...
Source